Development and preliminary validation of the multiattribute rhinitis symptom utility index

被引:90
作者
Revicki, DA
Leidy, NK
Brennan-Diemer, F
Thompson, C
Togias, A
机构
[1] MEDTAP Int Inc, Ctr Hlth Outcome Res, Bethesda, MD 20814 USA
[2] Johns Hopkins Asthma & Allergy Ctr, Baltimore, MD 21224 USA
关键词
rhinitis-related symptoms; health preferences; health-related quality of life; patient outcomes;
D O I
10.1023/A:1008860113818
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
The Rhinitis Symptom Utility Index (RSUI) was developed as a preference-based measure of rhinitis symptoms. The RSUI consist of ten questions on the severity and frequency of stuffy or blocked nose, runny nose, sneezing, itching, watery eyes and itching nose or throat over a 14 day period. A cross-sectional survey of 100 adults with allergic rhinitis was completed, with data collected on rhinitis history and severity, physician-rated rhinitis severity, the Rhinitis Quality of Life Questionnaire (RQLQ) and the Health Utilities Index Mark 2 (HUI2). The mean age of the patients was 37 +/- 11 years and 60% were female and 38% had a diagnosis of asthma. A multiplicative multiattribute utility function was developed from patient-derived preferences for different rhinitis-related symptom states. The mean RSUI score for this sample was 0.72 +/- 0.23, with a range of 0.15-1.0. Two week reproducibility of the RSUI was weak (ICC = 0.40). The index differentiated patients by physician-rated severity (p < 0.05) and was correlated 0.35 (p < 0.001) with the HUI2 and -0.67 (p < 0.001) with the RQLQ total score. The RSUI is brief and easy to administer and the results of this study support its reliability and validity. The modest reproducibility reflects the day to day variability of rhinitis. The RSUI may be a useful patient outcome for clinical trials and for cost-effectiveness studies comparing medical treatments for rhinitis.
引用
收藏
页码:693 / 702
页数:10
相关论文
共 24 条
  • [1] Bennett KJ, 1996, QUALITY LIFE PHARMAC, P253
  • [2] ASSESSMENT OF QUALITY-OF-LIFE IN PATIENTS WITH PERENNIAL ALLERGIC RHINITIS WITH THE FRENCH VERSION OF THE SF-36 HEALTH-STATUS QUESTIONNAIRE
    BOUSQUET, J
    BULLINGER, M
    FAYOL, C
    MARQUIS, P
    VALENTIN, B
    BURTIN, B
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1994, 94 (02) : 182 - 188
  • [3] Improvement of quality of life by treatment with cetirizine in patients with perennial allergic rhinitis as determined by a French version of the SF-36 questionnaire
    Bousquet, J
    Duchateau, J
    Pignat, JC
    Marquis, P
    Mariz, S
    Ware, JE
    Valentin, B
    Burtin, B
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1996, 98 (02) : 309 - 316
  • [4] The relationships between nasal hyperreactivity, quality of life, and nasal symptoms in patients with perennial allergic rhinitis
    deGraafintVeld, T
    Koenders, S
    Garrelds, IM
    vanWijk, RG
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1996, 98 (03) : 508 - 513
  • [5] DRUCE HM, 1992, ANN ALLERGY, V69, P53
  • [6] FEENY D, 1989, MED CARE, V27, P190
  • [7] Feeny D., 1996, QUALITY LIFE PHARMAC, P239
  • [8] Furlong W, 1990, GUIDE DESIGN DEV HLT
  • [9] IPRATROPIUM BROMIDE NASAL SPRAY IN NONALLERGIC RHINITIS - EFFICACY, NASAL CYTOLOGICAL RESPONSE AND PATIENT-EVALUATION ON QUALITY-OF-LIFE
    GEORGITIS, JW
    BANOV, C
    BOGGS, PB
    DOCKHORN, R
    GROSSMAN, J
    TINKELMAN, D
    ROSZKO, P
    WOOD, C
    [J]. CLINICAL AND EXPERIMENTAL ALLERGY, 1994, 24 (11) : 1049 - 1055
  • [10] Model for outcomes assessment of antihistamine use for seasonal allergic rhinitis
    Harvey, RP
    Comer, C
    Sanders, B
    Westley, R
    Marsh, W
    Shapiro, H
    Wiener, M
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1996, 97 (06) : 1233 - 1241